{"pageContent": "Background: Prostate cancer (PC) is the most common cancer in Western countries. More than one third of PC patients develop metastatic disease, and the 5-year expected survival in distant disease is about 35%. During the last few years, new treatments have been launched for metastatic castrate-resistant prostate cancer (mCRPC).", "metaData": {"source": "Novel biomarkers for prostate cancer: An evidence-based review for use in clinical practice\nhttps://pubmed.ncbi.nlm.nih.gov/28345187/"}}